Current status of bevacizumab for advanced hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a major cause of cancerrelated death worldwide, with at least 550,000 deaths each year, predominantly in Southeast Asia (1). The incidence of HCC has tripled in the last three decades in the United States, and is on the rise worldwide (2)